---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-053266"
form_type: "8-K"
ticker: "RFL"
cik: "0001713863"
company_name: "Rafael Holdings, Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T13:37:22.543166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rafael Holdings Q3 net loss narrows to $4.8M; Phase 3 data expected this month

## Summary
- Net loss attributable to Rafael Holdings of $4.8M ($0.19 per share) vs. $32.4M loss ($1.36) in Q3 last year.
- Cash and equivalents of $37.9M at April 30, 2025; $25M rights offering closed June 4 with net proceeds of $24.9M.
- Cyclo Therapeutics merger completed March 25, 2025; TransportNPC Phase 3 trial fully enrolled for NPC1.
- 48-week interim analysis results for Trappsol Cyclo expected later this month.
- R&D expenses rose to $3.0M and G&A to $3.2M due to Cyclo consolidation.

## SEC filing metadata
- accession: 0001213900-25-053266
- form_type: 8-K
- ticker: RFL
- cik: 0001713863
- company_name: Rafael Holdings, Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1713863/000121390025053266/0001213900-25-053266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1713863/000121390025053266/ea0245286-8k_rafael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-053266
- JSON: https://secwatch.observer/filing/0001213900-25-053266.json
- Plain text: https://secwatch.observer/filing/0001213900-25-053266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.